Treatments for menopausal and post-menopausal problems: present and future.
Probable developments in HRT and non-HRT treatments for menopausal and post-menopausal problems have been reviewed. More information is required on potential benefits and side-effects of HRT. The major potential benefit is prevention against stroke amelioration of Alzheimer's disease: the major potential side-effect discussed in this chapter is ovarian cancer. At present, techniques for delivering oestrogens are more varied and advanced than those for progestogens. Non-oral delivery systems for progestogens which minimize side-effects will be introduced during the next decade. It is not clear whether benefits expected with new progestational agents will be realized. Preliminary data suggest that SERMs and phytoestrogens are worthy of further evaluation. Their development will provoke intense interest over the next 10 years.
Whitehead
M
M
Menopause Clinic, Kings College School of Medicine & Dentistry, London, UK.
D000368:Aged; D000544:Alzheimer Disease / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D004965:Estrogen Antagonists / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000627:therapeutic use; D004968:Estrogens, Non-Steroidal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007529:Isoflavones; D008593:Menopause; D008875:Middle Aged; D048789:Phytoestrogens; D028321:Plant Preparations; D017698:Postmenopause; D011372:Progestins / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use
D004965:Estrogen Antagonists; D004967:Estrogens; D004968:Estrogens, Non-Steroidal; D007529:Isoflavones; D048789:Phytoestrogens; D028321:Plant Preparations; D011372:Progestins; D013629:Tamoxifen